New study discovers key predictive factors of improved BCVA in treatment of LHON disease
A new study led by Robert C. Sergott, MD, Chief of the Wills Eye Neuro-Ophthalmology Service, has found that key predictive factors of improved best-corrected visual acuity (BCVA) a year and a half after patients with Leber hereditary optic neuropathy (LHON) (caused by mt-ND4) receive GenSight Biologics’ investigational gene therapy lenadogene nolparvovec (Lumevoq) at least 6 months after disease onset.
“The study is the first to use spectral domain-optical coherence tomography (SD-OCT) and other clinical outcomes to identify predictive factors of BCVA changes 1.5 years after treatment,” said Sergott in the release.1 “The structural and functional evidence concurs that direct injection of lenadogene nolparvovec may be more effective than the contralateral therapeutic effect, thus supporting a recommendation to treat LHON patients bilaterally when possible.”